CNL announces project agreement for construction of its new Advanced Nuclear Materials Research Centre, the Canada Foundation for Innovation launches its flagship competition fund for 2023, SSHRC and Mitacs celebrate Canada’s researchers and innovators, and more.
Organization: Structural Genomics Consortium
Q&A: Dr. Richard Gold on why open science partnerships could reverse declining research productivity
Spending on scientific research has been rising for the last 50 years while, at the same time, researcher productivity has been dropping. That’s what Dr. Richard Gold, law professor and Director of the Centre for Intellectual Property Policy at McGill University, argues in a new paper that positions open science partnerships as a potential solution.
The Short Report, May 13, 2020: Public trust in science rising; new COVID-19 advisory councils created; OneEleven ceases operations; and more
COVID-19 NEWS Canadians’ trust in doctors, scientists and the government has increased since the cornovirus pandemic began, finds public opinion polls from January and repeated on May 1 and May 2. Conducted by Proof Strategies CanTrust Index of Ottawa, the survey found that 76% of Canadians trusted doctors and 70% trusted scientists. The follow up…
Ontario Budget 2019 takes “slice-and-dice” strategy to research funding
Ontario budget cuts more than $300 million in research and innovation funding
Structural Genomics Consortium expanding clinical and patient reach with new Phase IV funding
Canadian funding for the Toronto-based Structural Genomics Consortium (SGC) has been renewed, injecting $33 million into the ground breaking open innovation organization that determines the three-dimensional structure of proteins related to human diseases. The fourth phase of the public-private SGC will see an expansion its collaborative network to include disease and patient foundations while partnering with clinicians and research hospitals to validate new targets for drug discovery by testing its chemical probes on patients.
Editorial 31-7
The National Research Council is embarking on a re-alignment of its core strengths by reaching out to academia and other players in the federal innovation system (see lead article). NEOMED is making major strides retaining critical pharmaceutical talent in the Montreal region and its actively considering a third site for its potent combination of research expertise and business collaboration
Merck joins SGC, contributes $7.5 million
Merck & Co Inc is contributing $7.5 million to the Structural Genomics Consortium (SGC) as its newest corporate member. Merck’s decision to join the SGC was prompted by the organization’s status as a public-private partnership and its pioneering efforts to use open source intellectual property for moving technologies and medications into proprietary drug discovery programs.…
Merck joins SGC, contributes $7.5 million
Merck & Co Inc is contributing $7.5 million to the Structural Genomics Consortium (SGC) as its newest corporate member. Merck’s decision to join the SGC was prompted by the organization’s status as a public-private partnership and its pioneering efforts to use open source intellectual property for moving technologies and medications into proprietary drug discovery programs.…
SGC launches third phase with $49.9 million in funding
The Toronto-based Structural Genomics Consortium (SGC) has received $48.9 million to launch its third four-year phase. The funding is 30% less than in previous phases due primarily to the closure of the SGC laboratory at Karolinska Institutet in suburban Stockholm last June. The funding — 45% of which comes from commercial entities — will support…
Structural Genomics Consortium funding announced
Complete funding for the second phase of the Structural Genomics Consortium has been announced, with 13 partners (including three pharmaceutical firms) providing more than $105 million. The consortium — led by Dr Aled Edwards at the Univ of Toronto with three nodes in Toronto, the Univ of Oxford and the Karolinska Institutet — is dedicated…